Last reviewed · How we verify
NCT02430896
Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of Attention-Deficit/Hyperactivity Disorder (ADHD)
trial testing Methylphenidate (MPH) in Attention Deficit Disorder With Hyperactivity in 600 participants. Status unknown.
30 June 2020
Quick facts
| Lead sponsor | Asan Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 1 February 2015 |
| Primary completion | 30 June 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Methylphenidate (MPH) — full drug profile →
- Atomoxetine (ATOMOXETINE) — full drug profile →
Conditions studied
- Attention Deficit Disorder With Hyperactivity — all drugs for Attention Deficit Disorder With Hyperactivity →
Sponsor
Asan Medical Center
Who can join
Adults 6 to 12, any sex, with Attention Deficit Disorder With Hyperactivity. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Wide genome analysis regarding genetic polymorphisms as predictors of treatment response in Attention-Deficit/Hyperactivity Disorder(ADHD).
Time frame: visit 1 (-week 8)
Genome wide case-control association analysis will be operated with qualified phenotype and assigned intermittent phenotype. -
Neuroimaging analysis as predictors of treatment response in Attention-Deficit/Hyperactivity Disorder(ADHD).
Time frame: visit 1 (-week 8)
Thickness of cortex, anatomical relation will be compared with 3 tesla MRI. In addition, brain circuit for delayed aversion, delayed frustration, time processing and resting state. -
Drug effectiveness is assessed using ADHD rating scale, CGI -S (Clinical Global Impression - Severity scale) and CGI-I (Clinical Global Impression - Improvement scale).
Time frame: visit 1 (-week 8) -
Neuropsychological markers as the treatment response predictable factor of ADHD using a complex neuropsychological test consisting of SSRT, delayed aversion, delayed frustration, time processing, ATA
Time frame: visit 1 (-week 8)
Using a complex neuropsychological test consisting of The stop-signal reaction time (SSRT) task, delayed aversion, delayed frustration, time processing, Advanced tets of Attention (ATA). -
Comorbidity assessment using a composite measure consisting of K-PRC, C-SSRS, TCGI, and DCDQ
Time frame: visit1 (-week 8)
It is assessed using a composite measure consisting of Korean Personality Rating Scale for Children (K-PRC), Columbia Suicide Severity Rating Scale (C-SSRS), The Tic Severity Scale (TCGI), and The Developmental Coordination Disorder Questionnaire (DCDQ).
Sponsor's own description
The objective of this study is to identification of neuropsychological, genetic and neuroimaging markers and treatment response predictors of attention-deficit/hyperactivity disorder (ADHD). Participants who take the standardized pharmacotherapy (methylphenidate or atomoxetine) for ADHD will be observed for 52 weeks. They will do several neuropsychological, neuroimaging and genetic tests at visit 1\~6.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02430896
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Methylphenidate (MPH)
Trials testing the same drug.
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Other recruiting trials for Attention Deficit Disorder With Hyperactivity
Currently open trials in the same condition.
- NCT06974136 — tES Modalities for the Treatment of ADHD · NA · recruiting
- NCT06764810 — Association Between Motor Skills and Sensory Profiles in Children With Typical and Atypical Development Aged 4 to 11 Yea · recruiting
- NCT05621174 — The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD · NA · active not recruiting
- NCT06369714 — Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. · NA · recruiting
- NCT00001246 — Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers · active not recruiting
Other Asan Medical Center trials
Trials by the same sponsor.
- NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
- NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
- NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
- NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
- NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02430896 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
- Last refreshed: 2 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02430896.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing